FDA
- Status: approved
Belimumab plus Late Vaccination (Belimumab plus Late Vaccination) regulatory status in United States.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA has authorised it.
Human Genome Sciences Inc., a GSK Company is the originator. The local marketing authorisation holder may differ — check the official source linked above.